Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74


Deregulated expression and activity of Farnesyl Diphosphate Synthase (FDPS) in Glioblastoma.

Abate M, Laezza C, Pisanti S, Torelli G, Seneca V, Catapano G, Montella F, Ranieri R, Notarnicola M, Gazzerro P, Bifulco M, Ciaglia E.

Sci Rep. 2017 Oct 26;7(1):14123. doi: 10.1038/s41598-017-14495-6.


N6-isopentenyladenosine dual targeting of AMPK and Rab7 prenylation inhibits melanoma growth through the impairment of autophagic flux.

Ranieri R, Ciaglia E, Amodio G, Picardi P, Proto MC, Gazzerro P, Laezza C, Remondelli P, Bifulco M, Pisanti S.

Cell Death Differ. 2018 Feb;25(2):353-367. doi: 10.1038/cdd.2017.165. Epub 2017 Oct 13.


Recognition by natural killer cells of N6-isopentenyladenosine-treated human glioma cell lines.

Ciaglia E, Laezza C, Abate M, Pisanti S, Ranieri R, D'alessandro A, Picardi P, Gazzerro P, Bifulco M.

Int J Cancer. 2018 Jan 1;142(1):176-190. doi: 10.1002/ijc.31036. Epub 2017 Sep 21.


The mystery of longevity in Cilento: a mix of a good dose of genetic predisposition and a balanced diet based on the Mediterranean model.

Bifulco M, Pisanti S.

Eur J Clin Nutr. 2017 Aug;71(8):1020-1021. doi: 10.1038/ejcn.2017.91. Epub 2017 May 31. No abstract available.


The isoprenoid derivative N6 -benzyladenosine CM223 exerts antitumor effects in glioma patient-derived primary cells through the mevalonate pathway.

Ciaglia E, Grimaldi M, Abate M, Scrima M, Rodriquez M, Laezza C, Ranieri R, Pisanti S, Ciuffreda P, Manera C, Gazzerro P, D'Ursi AM, Bifulco M.

Br J Pharmacol. 2017 Jul;174(14):2287-2301. doi: 10.1111/bph.13824. Epub 2017 Jun 11.


Cannabidiol: State of the art and new challenges for therapeutic applications.

Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, Abate M, Faggiana G, Proto MC, Fiore D, Laezza C, Bifulco M.

Pharmacol Ther. 2017 Jul;175:133-150. doi: 10.1016/j.pharmthera.2017.02.041. Epub 2017 Feb 22. Review.


The complex interplay among hepatocytes and immune cells at the crossroad between inflammation and cholesterol metabolism in hyperglycemia.

Bifulco M, Pisanti S, Ciaglia E.

Endocrine. 2017 Oct;58(1):21-23. doi: 10.1007/s12020-017-1254-0. Epub 2017 Feb 8. Review.


Modern History of Medical Cannabis: From Widespread Use to Prohibitionism and Back.

Pisanti S, Bifulco M.

Trends Pharmacol Sci. 2017 Mar;38(3):195-198. doi: 10.1016/ Epub 2017 Jan 14. No abstract available.


Antiglioma effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, through the downregulation of epidermal growth factor receptor.

Ciaglia E, Abate M, Laezza C, Pisanti S, Vitale M, Seneca V, Torelli G, Franceschelli S, Catapano G, Gazzerro P, Bifulco M.

Int J Cancer. 2017 Feb 15;140(4):959-972. doi: 10.1002/ijc.30505. Epub 2016 Nov 16.


Dental care and dentistry practice in the Medieval Medical School of Salerno.

Bifulco M, Amato M, Gangemi G, Marasco M, Caggiano M, Amato A, Pisanti S.

Br Dent J. 2016 Jul 22;221(2):87-9. doi: 10.1038/sj.bdj.2016.528.


Immuno-Modulatory Properties of a Quinolin-2-(1H)-on-3-Carboxamide Derivative: Relevance in Multiple Sclerosis.

Malfitano AM, Laezza C, Pisanti S, Manera C, Bifulco M.

Recent Pat CNS Drug Discov. 2016;10(2):113-121.


p53 regulates the mevalonate pathway in human glioblastoma multiforme.

Laezza C, D'Alessandro A, Di Croce L, Picardi P, Ciaglia E, Pisanti S, Malfitano AM, Comegna M, Faraonio R, Gazzerro P, Bifulco M.

Cell Death Dis. 2015 Oct 15;6:e1909. doi: 10.1038/cddis.2015.279.


Antitumor effect of pyrrolo-1,5-benzoxazepine-15 and its synergistic effect with Oxaliplatin and 5-FU in colorectal cancer cells.

Fiore D, Proto MC, Pisanti S, Picardi P, Pagano Zottola AC, Butini S, Gemma S, Casagni A, Laezza C, Vitale M, Ligresti A, Di Marzo V, Zisterer DM, Nathwani S, Williams DC, Campiani G, Gazzerro P, Bifulco M.

Cancer Biol Ther. 2016 Aug 2;17(8):849-58. doi: 10.1080/15384047.2015.1078028.


Cannabinoid receptor CB1 regulates STAT3 activity and its expression dictates the responsiveness to SR141716 treatment in human glioma patients' cells.

Ciaglia E, Torelli G, Pisanti S, Picardi P, D'Alessandro A, Laezza C, Malfitano AM, Fiore D, Pagano Zottola AC, Proto MC, Catapano G, Gazzerro P, Bifulco M.

Oncotarget. 2015 Jun 20;6(17):15464-81.


New quinolone- and 1,8-naphthyridine-3-carboxamides as selective CB2 receptor agonists with anticancer and immuno-modulatory activity.

Manera C, Malfitano AM, Parkkari T, Lucchesi V, Carpi S, Fogli S, Bertini S, Laezza C, Ligresti A, Saccomanni G, Savinainen JR, Ciaglia E, Pisanti S, Gazzerro P, Di Marzo V, Nieri P, Macchia M, Bifulco M.

Eur J Med Chem. 2015 Jun 5;97:10-8. doi: 10.1016/j.ejmech.2015.04.034. Epub 2015 Apr 24.


Anandamide drives cell cycle progression through CB1 receptors in a rat model of synchronized liver regeneration.

Pisanti S, Picardi P, Pallottini V, Martini C, Petrosino S, Proto MC, Vitale M, Laezza C, Gazzerro P, Di Marzo V, Bifulco M.

J Cell Physiol. 2015 Dec;230(12):2905-14. doi: 10.1002/jcp.24959.


Medicinal use of cannabis in Europe: the fact that more countries legalize the medicinal use of cannabis should not become an argument for unfettered and uncontrolled use.

Bifulco M, Pisanti S.

EMBO Rep. 2015 Feb;16(2):130-2. doi: 10.15252/embr.201439742. Epub 2015 Jan 9. No abstract available.


Enrichment of CD56(dim)KIR + CD57 + highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients.

Ali TH, Pisanti S, Ciaglia E, Mortarini R, Anichini A, Garofalo C, Tallerico R, Santinami M, Gulletta E, Ietto C, Galgani M, Matarese G, Bifulco M, Ferrone S, Colucci F, Moretta A, Kärre K, Carbone E.

Nat Commun. 2014 Dec 4;5:5639. doi: 10.1038/ncomms6639.


The basis of the modern medical hygiene in the medieval Medical School of Salerno.

Bifulco M, Capunzo M, Marasco M, Pisanti S.

J Matern Fetal Neonatal Med. 2015;28(14):1691-3.


Anandamide inhibits breast tumor-induced angiogenesis.

Picardi P, Ciaglia E, Proto M, Pisanti S.

Transl Med UniSa. 2014 Apr 8;10:8-12. eCollection 2014 Sep.


N6-isopentenyladenosine affects cytotoxic activity and cytokines production by IL-2 activated NK cells and exerts topical anti-inflammatory activity in mice.

Ciaglia E, Pisanti S, Picardi P, Laezza C, Sosa S, Tubaro A, Vitale M, Gazzerro P, Malfitano AM, Bifulco M.

Pharmacol Res. 2014 Nov;89:1-10. doi: 10.1016/j.phrs.2014.07.003. Epub 2014 Jul 22.


Novel prospects of statins as therapeutic agents in cancer.

Pisanti S, Picardi P, Ciaglia E, D'Alessandro A, Bifulco M.

Pharmacol Res. 2014 Oct;88:84-98. doi: 10.1016/j.phrs.2014.06.013. Epub 2014 Jul 5. Review.


Antiangiogenic effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, mediated by AMPK activation.

Pisanti S, Picardi P, Ciaglia E, Margarucci L, Ronca R, Giacomini A, Malfitano AM, Casapullo A, Laezza C, Gazzerro P, Bifulco M.

FASEB J. 2014 Mar;28(3):1132-44. doi: 10.1096/fj.13-238238. Epub 2013 Nov 21.


"Adiponcosis": a new term to name the obesity and cancer link.

Bifulco M, Pisanti S.

J Clin Endocrinol Metab. 2013 Dec;98(12):4664-5. doi: 10.1210/jc.2013-2645. Epub 2013 Oct 9. No abstract available.


Immune-modulation and properties of absorption and blood brain barrier permeability of 1,8-naphthyridine derivatives.

Malfitano AM, Laezza C, Saccomanni G, Tuccinardi T, Manera C, Martinelli A, Ciaglia E, Pisanti S, Vitale M, Gazzerro P, Bifulco M.

J Neuroimmune Pharmacol. 2013 Dec;8(5):1077-86. doi: 10.1007/s11481-013-9494-0. Epub 2013 Oct 1.


N6-isopentenyladenosine, an endogenous isoprenoid end product, directly affects cytotoxic and regulatory functions of human NK cells through FDPS modulation.

Ciaglia E, Pisanti S, Picardi P, Laezza C, Malfitano AM, D'Alessandro A, Gazzerro P, Vitale M, Carbone E, Bifulco M.

J Leukoc Biol. 2013 Dec;94(6):1207-19. doi: 10.1189/jlb.0413190. Epub 2013 Jul 11.


The endocannabinoid signaling system in cancer.

Pisanti S, Picardi P, D'Alessandro A, Laezza C, Bifulco M.

Trends Pharmacol Sci. 2013 May;34(5):273-82. doi: 10.1016/ Epub 2013 Apr 17. Review.


Anandamide inhibits the Wnt/β-catenin signalling pathway in human breast cancer MDA MB 231 cells.

Laezza C, D'Alessandro A, Paladino S, Maria Malfitano A, Chiara Proto M, Gazzerro P, Pisanti S, Santoro A, Ciaglia E, Bifulco M; Endocannabinoid Research Group.

Eur J Cancer. 2012 Nov;48(16):3112-22. doi: 10.1016/j.ejca.2012.02.062. Epub 2012 Mar 14.


Pharmacological actions of statins: a critical appraisal in the management of cancer.

Gazzerro P, Proto MC, Gangemi G, Malfitano AM, Ciaglia E, Pisanti S, Santoro A, Laezza C, Bifulco M.

Pharmacol Rev. 2012 Jan;64(1):102-46. doi: 10.1124/pr.111.004994. Epub 2011 Nov 21. Review.


Genetic and pharmacologic inactivation of cannabinoid CB1 receptor inhibits angiogenesis.

Pisanti S, Picardi P, Prota L, Proto MC, Laezza C, McGuire PG, Morbidelli L, Gazzerro P, Ziche M, Das A, Bifulco M.

Blood. 2011 May 19;117(20):5541-50. doi: 10.1182/blood-2010-09-307355. Epub 2011 Apr 1.


Effects of olive oil polyphenols on fatty acid synthase gene expression and activity in human colorectal cancer cells.

Notarnicola M, Pisanti S, Tutino V, Bocale D, Rotelli MT, Gentile A, Memeo V, Bifulco M, Perri E, Caruso MG.

Genes Nutr. 2011 Feb;6(1):63-9. doi: 10.1007/s12263-010-0177-7. Epub 2010 May 16.


Interaction of endocannabinoid system and steroid hormones in the control of colon cancer cell growth.

Proto MC, Gazzerro P, Di Croce L, Santoro A, Malfitano AM, Pisanti S, Laezza C, Bifulco M.

J Cell Physiol. 2012 Jan;227(1):250-8. doi: 10.1002/jcp.22727.


Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and of Ras farnesylation mediate antitumor effects of anandamide in human breast cancer cells.

Laezza C, Malfitano AM, Proto MC, Esposito I, Gazzerro P, Formisano P, Pisanti S, Santoro A, Caruso MG, Bifulco M.

Endocr Relat Cancer. 2010 May 18;17(2):495-503. doi: 10.1677/ERC-10-0009. Print 2010 Jun.


Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin.

Gazzerro P, Malfitano AM, Proto MC, Santoro A, Pisanti S, Caruso MG, Notarnicola M, Messa C, Laezza C, Misso G, Caraglia M, Bifulco M.

Oncol Rep. 2010 Jan;23(1):171-5.


End of the line for cannabinoid receptor 1 as an anti-obesity target? An opinion.

Bifulco M, Pisanti S.

Nat Rev Drug Discov. 2009 Jul;8(7):594. doi: 10.1038/nrd2775-c1. No abstract available.


Endocannabinoid system modulation in cancer biology and therapy.

Pisanti S, Bifulco M.

Pharmacol Res. 2009 Aug;60(2):107-16. doi: 10.1016/j.phrs.2009.03.011. Epub 2009 Mar 24. Review.


Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colon.

Santoro A, Pisanti S, Grimaldi C, Izzo AA, Borrelli F, Proto MC, Malfitano AM, Gazzerro P, Laezza C, Bifulco M.

Int J Cancer. 2009 Sep 1;125(5):996-1003. doi: 10.1002/ijc.24483.


Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents.

Pisanti S, Malfitano AM, Grimaldi C, Santoro A, Gazzerro P, Laezza C, Bifulco M.

Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):117-31. doi: 10.1016/j.beem.2009.02.001. Review.


Dietary recommendations in the medieval Medical School of Salerno: a lesson from the past.

Bifulco M, Marasco M, Pisanti S.

Am J Prev Med. 2008 Dec;35(6):602-3. doi: 10.1016/j.amepre.2008.07.004. No abstract available.


Lovastatin induces apoptosis of k-ras-transformed thyroid cells via inhibition of ras farnesylation and by modulating redox state.

Laezza C, Fiorentino L, Pisanti S, Gazzerro P, Caraglia M, Portella G, Vitale M, Bifulco M.

J Mol Med (Berl). 2008 Dec;86(12):1341-51. doi: 10.1007/s00109-008-0396-1. Epub 2008 Sep 9.


The anandamide analog, Met-F-AEA, controls human breast cancer cell migration via the RHOA/RHO kinase signaling pathway.

Laezza C, Pisanti S, Malfitano AM, Bifulco M.

Endocr Relat Cancer. 2008 Dec;15(4):965-74. doi: 10.1677/ERC-08-0030. Epub 2008 Aug 1.


Endocannabinoids in endocrine and related tumours.

Bifulco M, Malfitano AM, Pisanti S, Laezza C.

Endocr Relat Cancer. 2008 Jun;15(2):391-408. doi: 10.1677/ERC-07-0258. Review.


Reply to the letter to the editor "Long-term cannabinoid receptor (CB1) blockade in obesity: implications for the development of colorectal cancer".

Santoro A, Gazzerro P, Malfitano AM, Pisanti S, Laezza C, Bifulco M.

Int J Cancer. 2008 Jul 1;123(1):243-4. doi: 10.1002/ijc.23507. No abstract available.


Rimonabant (SR141716) exerts anti-proliferative and immunomodulatory effects in human peripheral blood mononuclear cells.

Malfitano AM, Laezza C, Pisanti S, Gazzerro P, Bifulco M.

Br J Pharmacol. 2008 Mar;153(5):1003-10. Epub 2007 Dec 24.


Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects.

Bifulco M, Grimaldi C, Gazzerro P, Pisanti S, Santoro A.

Mol Pharmacol. 2007 Jun;71(6):1445-56. Epub 2007 Feb 27. Review.


Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy.

Pisanti S, Borselli C, Oliviero O, Laezza C, Gazzerro P, Bifulco M.

J Cell Physiol. 2007 May;211(2):495-503.


Anandamide inhibits Cdk2 and activates Chk1 leading to cell cycle arrest in human breast cancer cells.

Laezza C, Pisanti S, Crescenzi E, Bifulco M.

FEBS Lett. 2006 Nov 13;580(26):6076-82. Epub 2006 Oct 12.


The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism.

Sarnataro D, Pisanti S, Santoro A, Gazzerro P, Malfitano AM, Laezza C, Bifulco M.

Mol Pharmacol. 2006 Oct;70(4):1298-306. Epub 2006 Jul 5.


Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma.

Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, De Petrocellis L, Laezza C, Portella G, Bifulco M, Di Marzo V.

J Pharmacol Exp Ther. 2006 Sep;318(3):1375-87. Epub 2006 May 25.


Cannabinoids and cancer: pros and cons of an antitumour strategy.

Bifulco M, Laezza C, Pisanti S, Gazzerro P.

Br J Pharmacol. 2006 May;148(2):123-35. Review.

Supplemental Content

Loading ...
Support Center